<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495830</url>
  </required_header>
  <id_info>
    <org_study_id>STRATIFY</org_study_id>
    <nct_id>NCT03495830</nct_id>
  </id_info>
  <brief_title>Stratification of Patient With Carotid Disease</brief_title>
  <acronym>TAXINOMISIS</acronym>
  <official_title>Observational Multicentre Clinical Trial for Validation of Taxinomisis, New Stratification Tool for Stroke Risk in Patients With Carotid Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Belgrade</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Genova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Utrecht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Belgrade</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Taxinomisis trial is part of the Taxinomisis project. The concept of the
      Taxinomisis project is to stratify carotid artery disease relying on new modern data
      corresponding to contemporary patients based on information from longitudinal studies.
      Taxinomisis trial will validate this tool and adjust such stratification. Initial step of the
      project is characterization of symptomatic and asymptomatic carotid atherosclerotic plaque
      lesions, identification of risk and susceptibility factors through the exploitation of
      longitudinal cohort data and multiomics and disintegration of carotid artery disease
      phenotypes into endotypes through joint modeling of multipleomics data sets and systems
      medicine approaches. Finally such stratification model will be validated and adjusted in the
      Taxinomisis clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the trial is to validate TAXINOMISIS system for risk stratification of carotid artery
      stenotic disease. Primary endpoints are stroke, transitory ischemic attack or retinal symptom
      while secondary endpoints are MRI silent brain lesions and carotid plaque progression.

      Patient with moderate to severe extra-cranial, both asymptomatic and symptomatic, carotid
      artery stenosis will be enrolled in the prospective observational multi-center trial in five
      European (Athens, Barcelona, Belgrade, Genoa, Munich and Utrecht) vascular centers. Inclusion
      will last from 31.3.2018 - 01.06.2019. Patients with short life expectancy, high potential of
      stroke from other cause or patients with complex and tandem carotid lesions will be excluded
      from the trial.

      Included patients will be examined clinically, basic laboratory exam will be performed and
      part of blood specimen will be stored and assessed later. Carotid plaque will be analysed by
      means of duplex and MRI image while brain lesions will be detected on brain MRI.

      Treatment strategy will be dependent on guidelines of good clinical practice and let
      independently to institutional multidisciplinary panelist board. In patients treated with
      carotid endarterectomy (CEA) carotid plaque will be stored and assessed for future analysis.
      In respect to allocated therapy patients will follow different follow up protocols.

      Intervention group: Patients undergoing intervention CEA or carotid artery stenting (CAS),
      will be followed by clinical examination and carotid duplex on 12, 24 and 36 month. If there
      is coexisting contralateral carotid stenosis greater than 50% and not requiring
      interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.

      Optimal medical therapy group: Patients not subjected to intervention (or in whom one carotid
      has been treated with CAS or CEA and contra-lateral stenosis is greater than 50%) will be
      followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from
      aortic arch up to the circle of Willis after 12 and 36 months.

      Trial plans to recruit 270 patients distributed in participating centers based on individual
      capabilities of each center. The diagnostic performance of the new risk model, and its
      accuracy to discriminate high versus low risk cases for cerebrovascular complications from
      carotid artery disease will be evaluated using Receiver Operating Characteristic (ROC) curve
      analysis. The accuracy (discriminated ability) of the model will be assessed by measuring the
      Area under the ROC curve (AUC). An AUC 0.80 and 90% CI, for the sensitivity of prediction
      model of 80% with marginal error of 10%, will be targeted.

      Trial will terminate after finalizing 36 months of follow up for included patients at June
      2022.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Combined stroke, transitory ischemic attach and retinal transitory ischemic attach</measure>
    <time_frame>3 years</time_frame>
    <description>rapidly developing clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular origin with CT or MRI confirmation of ischemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Silent brain lesions</measure>
    <time_frame>3 years</time_frame>
    <description>ischemic lesions in the brain</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Carotid endarterectomy</arm_group_label>
    <description>Patients that underwent intervention (CEA or CAS) are followed by clinical examination and carotid duplex on 12, 24 and 36 month If there is coexisting contralateral carotid stenosis with grade greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal medical therapy group</arm_group_label>
    <description>Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contralateral has stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid endarterectomy</intervention_name>
    <description>Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.</description>
    <arm_group_label>Carotid endarterectomy</arm_group_label>
    <arm_group_label>Optimal medical therapy group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At the inclusion in study, after 12,24 and 36 months blood samples will be analyzed, while 10
      ml of blood sample will be stored for further analysis.

      Patients treated with carotid endarterectomy will have their plaque stored and analysed.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with extracranial carotid stenosis greater than 50% stenosis (NASCET) in the
        carotid bifurcation or internal carotid artery assessed by means of ultrasound
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Extracranial carotid stenosis greater than 50% stenosis (NASCET) in the carotid
             bifurcation or internal carotid artery assessed by means of ultrasound;

          -  Ability of the patient for follow-up examinations;

          -  Personally signed informed consent

        Exclusion Criteria:

          -  Previous haemorrhagic stroke,

          -  Non-atherosclerotic carotid stenosis (e.g. dissection, floating thrombus,
             fibromuscular dysplasia, postirradiation lesion)

          -  Presence of stenotic lesions in the proximal common carotid artery,

          -  Recurrent carotid stenosis after CEA or CAS,

          -  Carotid aneurysm

          -  Bilateral carotid occlusion,

          -  Severe aortic arch calcifications and shaggy aorta

          -  Intracranial angioma or aneurysms,

          -  Severe pre-existing disability (modified Rankin scale â‰¥ 3);

          -  Contraindications for heparin, ASA and clopidogrel therapy

          -  Contraindication for MRI examination (metal implants, claustrophobia);

          -  Increased risk of thrombotic or embolic events (congenital or acquired thrombotic
             conditions, active untreated cancer, atrial fibrillation, severe cardiomyopathy with
             ejection fraction lower than 30%);

          -  Planned major surgery and/or life expectancy less than 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Fotiadis, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Ionania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Themis Exarchos, PhD</last_name>
    <phone>00306947709387</phone>
    <email>themis.exarchos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vassilisa Potsika, PhD</last_name>
    <email>vpotsika@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaroslav Pelisek</last_name>
      <email>pelisek@gmx.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gert Jan de Borst, PhD</last_name>
      <email>G.J.deBorst-2@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Gerard Pasterkamp</last_name>
      <email>g.pasterkamp@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinic for Vascular and Endovascular Surgery, Serbian Clinical Centre</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Koncar, MD</last_name>
      <phone>+381668300290</phone>
      <email>dr.koncar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Igor Koncar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincente Riambau, PhD</last_name>
      <email>VRIAMBAU@clinic.cat</email>
    </contact>
    <contact_backup>
      <last_name>Gaspar Mestres, PhD</last_name>
      <email>gasparmestres@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Belgrade</investigator_affiliation>
    <investigator_full_name>Igor Koncar</investigator_full_name>
    <investigator_title>Vascular surgeon,PhD, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

